- Home
- SMHI vs CTNM Comparison
SMHI vs CTNM Comparison
Compare SMHI & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMHI
- CTNM
- Stock Information
- Founded
- SMHI 1989
- CTNM 2009
- Country
- SMHI United States
- CTNM United States
- Employees
- SMHI N/A
- CTNM N/A
- Industry
- SMHI Marine Transportation
- CTNM
- Sector
- SMHI Consumer Discretionary
- CTNM
- Exchange
- SMHI Nasdaq
- CTNM Nasdaq
- Market Cap
- SMHI 142.2M
- CTNM 114.1M
- IPO Year
- SMHI N/A
- CTNM 2024
- Fundamental
- Price
- SMHI $5.34
- CTNM $3.66
- Analyst Decision
- SMHI
- CTNM Strong Buy
- Analyst Count
- SMHI 0
- CTNM 4
- Target Price
- SMHI N/A
- CTNM $22.50
- AVG Volume (30 Days)
- SMHI 98.1K
- CTNM 102.0K
- Earning Date
- SMHI 04-30-2025
- CTNM 05-14-2025
- Dividend Yield
- SMHI N/A
- CTNM N/A
- EPS Growth
- SMHI N/A
- CTNM N/A
- EPS
- SMHI N/A
- CTNM N/A
- Revenue
- SMHI $264,089,999.00
- CTNM N/A
- Revenue This Year
- SMHI $4.13
- CTNM N/A
- Revenue Next Year
- SMHI $8.55
- CTNM N/A
- P/E Ratio
- SMHI N/A
- CTNM N/A
- Revenue Growth
- SMHI N/A
- CTNM N/A
- 52 Week Low
- SMHI $3.63
- CTNM $3.35
- 52 Week High
- SMHI $15.36
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- SMHI 57.17
- CTNM N/A
- Support Level
- SMHI $4.84
- CTNM N/A
- Resistance Level
- SMHI $5.54
- CTNM N/A
- Average True Range (ATR)
- SMHI 0.25
- CTNM 0.00
- MACD
- SMHI 0.04
- CTNM 0.00
- Stochastic Oscillator
- SMHI 71.43
- CTNM 0.00
About SMHI SEACOR Marine Holdings Inc.
Seacor Marine Holdings Inc provides marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that deliver cargo and personnel to offshore installations, including wind farms, handle anchors, and mooring equipment for offshore rigs and platforms. Its geographical segment includes the United States (Gulf of Mexico), Africa and Europe, Middle East and Asia, and Latin America.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.